Heparins Outperform DOACs and FXII/FXI Inhibitors in Preventing Thrombin Generation: JTH Study
Journal of Thrombosis and Haemostasis (JTH) shared an insightful post on LinkedIn:
“Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study
This in vitro catheter-initiated thrombin generation model compared heparins, DOACs, and emerging FXII/FXI inhibitors. Heparins were the most effective, with UFH completely suppressing thrombin generation at clinically relevant concentrations. DOACs and fondaparinux showed limited efficacy, while FXII/FXI inhibitors (asundexian, milvexian, garadacimab, abelacimab) did not adequately prevent coagulation on artificial surfaces. Results align with clinical observations, reinforcing UFH as the gold standard in invasive endovascular procedures.”
Read the full article here:
Article: Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study
Authors: Michael Hardy, Henri Thonon, Jonathan Douxfils, Julie Vassart, Isabelle Gouin–Thibault, Sarah Lessire, Thomas Lecompte, Francois
Stay updated with Hemostasis Today.
-
Sep 5, 2025, 14:06Thrombosis Update: VTE Death Rate 3X Higher in Los Angeles Jails Than General Population
-
Sep 4, 2025, 22:00Shivani Modi Highlights SOHO 2025 Study Linking Elevated WBC Counts to Increased Thrombosis Risk
-
Sep 4, 2025, 22:00Cancer, Clots and Communication: Register Now for The Upcoming Webinar on CAT!
-
Sep 4, 2025, 11:52PARTHENOPE Trial: A New Benchmark in Risk Score Validation
-
Sep 4, 2025, 09:46SOHO 2025: Exploring AI in Hematology and Oncology
-
Sep 5, 2025, 14:04Melasma Treatment Advances: Non-Ablative Laser and Tranexamic Acid Combination Explained
-
Sep 5, 2025, 12:55RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
-
Sep 5, 2025, 12:18Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg's Efficacy for Essential Thrombocythemia
-
Sep 5, 2025, 06:28Digital Twin Study Predicts Higher Thrombotic Recurrence with DOACs vs VKAs in APS Patients
-
Sep 4, 2025, 22:00Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 5, 2025, 14:12EAHAD Podcast: Reducing Pain and Distress in Children Receiving Emicizumab
-
Sep 5, 2025, 03:18Pier Mannuccio Mannucci on How Green Spaces and Physical Activity Can Help Prevent Heart Failure
-
Sep 5, 2025, 02:15Abdul Mannan Explains How DOACs Can Confuse Lupus Anticoagulant Testing
-
Sep 4, 2025, 11:55Sumyea Kabir Highlights the Critical Role of Safe Donors in Blood Transfusion Safety
-
Sep 3, 2025, 14:18Living with Factor V Deficiency: Helen’s Inspiring Story on Haemnet Haemcast